
Home » Pipeline
Pipeline
Company | Drug/Device | Medical Condition | Status |
---|---|---|---|
Verastem | Copiktra | Leukemia | Granted approval by the FDA |
MT.DERM GmbH | Exceed, microneedling device | Facial wrinkles | Granted clearance by the FDA |
Cook Medical | 5 mm diameter version of Zilver® PTX® | Peripheral artery disease (PAD) | Granted clearance by the FDA |
Avita Medical | RECELL® Autologous Cell Harvesting Device (RECELL® System) | Severe thermal burns in patients 18 and older | Granted clearance by the FDA |
Cardurion Pharmaceuticals | CRD-733, a Phosphodiesterase-9 (PDE-9) inhibitor | Heart failure | FDA has accepted Investigational New Drug Application (IND) |
OBI Pharma, Inc. | OBI-3424 | Acute Lymphoblastic Leukemia (ALL) | Granted Orphan Drug Designation by FDA |
Alnylam Pharmaceuticals | Givosiran | Acute hepatic porphyrias (AHPs) | Successful early Phase III clinical trial results announced |
AstraZeneca | Imfinzi (durvalumab) | Non-small cell lung cancer (NSCLC) | Phase III PACIFIC clinical trial found cut deaths by a third |
Genentech | Tecentriq plus chemotherapy | Extensive-stage small cell lung cancer (ES-SCLC) | Phase III trial showed treatment helped patients live significantly longer than chemo alone |
Daiichi Sankyo Company, Ltd | Trastuzumab deruxtecan (DS-8201) | Previously-treated HER2 positive unresectable and/or metastatic breast cancer | Initiated two Phase III trials |
Aurinia Pharmaceuticals, Inc. | Voclosporin added to background therapy of mycophenolate mofetil (MMF)/CellCept® | Lupus nephritis (LN) | Completed enrollment in AURORA Phase III clinical trial |
Catabasis Pharmaceuticals, Inc. | Edasalonexent | Duchenne muscular dystrophy (DMD) | Initiated Polaris DMD Phase III clinical trial |
AstraZeneca | Farxiga (dapagliflozin) | Cardiovascular disease | Positive Phase III clinical trial results announced |
Alexion Pharmaceuticals, Inc. | Soliris® (eculizumab) | Anti-aquaporin-4 (AQP4) auto antibody-positive neuromyelitis optica spectrum disorder (NMOSD) | Positive topline results from the Phase III PREVENT announced |
Upcoming Events
-
05Dec
-
14Apr